The Foundation for the National Institutes of Health (FNIH) announces the appointment of Elizabeth Andrews, Vice President, Pharmacoepidemiology and Risk Management at RTI Health Solutions to the Executive Board of the Observational Medical Outcomes Partnership (OMOP).
The London School of Hygiene and Tropical Medicine (LSHTM), a leading medical institution in Europe for research and postgraduate education will offer the course "Practical Pharmacoepidemiology" September 17-20, 2012.
The course is designed for postgraduate students with a basic grounding...
Alejandro Arana, MD, a pharmacoepidemiologist with over 15 years of experience, joined RTI Health Solutions (RTI-HS) as a Director of Epidemiology. He will be based in our Barcelona, Spain office.
Susana Perez-Gutthann, RTI Health Solutions Vice President and Global Head of Epidemiology will speak at the 2nd Joint DIA/EMA ENCePP to be held at the...
Susana Perez-Gutthann, RTI Health Solutions Vice President and Global Head of Epidemiology, will be a speaker at the Swedish Society for Pharmacoepidemiology 20th anniversary celebration event to be held on Wednesday October 19 at the Nobel Forum, Karolinska Institutet in Stockholm, Sweden.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has published the scientific report "Conjoint Analysis Applications in Health - a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force".
A shortage of oncologists and rising costs of chemotherapy and radiation therapies and imaging tests, are making delivering quality cancer care increasingly difficult, according to a new review by researchers at RTI Health Solutions and Eli Lilly and Company.
Using aspirin for coronary heart prevention is less costly and more effective than doing nothing in men older than 45 with more than 10 percent 10-year-risk of the disease, according to a study by researchers at RTI Health Solutions, University of Michigan, and University of North Carolina at...
RTI Health Solutions has been awarded a project by the Critical Path Institute (C-Path) to create a standard, comprehensive symptom measure for use in irritable bowel syndrome (IBS) clinical trials.